Acute viral hepatitis (C-genotype 6a and B) acquired during kidney transplantation by two patients and review of the literature

Clinical Nephrology

Volumn 72, Issue 6, 2009, Pages 482-487

  Rogachev, B ^a   Virobiov, M ^a   Shnaider, A ^a   Hausmann, M ^a   Zlotnik, M ^a   Basok, A ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Ethical aspects; Hepatitis C and B contamination; Living unrelated kidney transplantation

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BASILIXIMAB; CD4 ANTIGEN; CYCLOSPORIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TERLIPRESSIN; THYMOCYTE ANTIBODY;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; ASCITES; CASE REPORT; CHRONIC KIDNEY DISEASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GLOMERULITIS; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; HYPERVOLEMIA; JAUNDICE; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVING DONOR; LYMPHOCYTIC INFILTRATION; MALE; OLIGURIA; THROMBOCYTOPENIA; UREMIA; URINE VOLUME;

ACUTE DISEASE; ADULT; DNA, VIRAL; FATAL OUTCOME; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 71449093510     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CNX06288     Document Type: Article

References (28)

1. Gottesdiener KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med. 1989; 110: 1001-1016.
2. Ingsathit A, Thakkinstian A, Kantachuvesiri S, Sumethkul V. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc. 2007; 39: 1424-1428.
3. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005; 12: 2913-2921.
4. Chan TM, Wu PC, Lau JY, Lai CL, Lok AS, Cheng IK. Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation. 1994; 58: 996-1000.
5. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and post-transplantation treatment. Clin J Am Soc Nephrol. 2007; 3: 563-575.
6. Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat. 2001; 4: 287-292.
7. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995; 59: 1426-1431.
8. Shu KH, Lan JL,Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation. 2004; 77: 1894-1896.
9. Delladetsima I, Psichogiou M, Sypsa V, Psimenou E, Kostakis A, Hatzakis A, Boletis JN. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis. 2006; 47: 309-316.
10. Davis GL. Viral hepatitis in the immunocompromised host. In: Willson RA (ed). Viral hepatitis: diagnosis, treatment, prevention. New York, NY: Marcel Dekker; 1997. p. 471-503.
11. Ko WJ, Chou NK, Hsu RB, Chen YS,Wang SS, Chu SH, Lai MY. Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area. J Heart Lung Transplant. 2001; 8: 865-875.
12. Fabrizi F, DulaiG, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation. 2004; 77: 859-864.
13. Tsang WK, Tong KL, Chan HW. Lamivudine therapy in renal allograft recipients with hepatitis B virus infection. Transplant Proc. 2003; 1: 278-279.
14. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant. 2004; 4: 1103-1109.
15. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119: 172-180.
16. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation. 1997; 64: 1624-1627.
17. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000; 32: 635-639.
18. Huang YW, Liu CJ, Lai MY, Lee PH, Tsai MK, Wang SS, Lai MK, Kao JH. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. Clin Ther. 2006; 28: 1327-1334.
19. de Silva HJ, Dassanayake AS, Manamperi A, de Silva AP. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc. 2006; 38: 3118-3120.
20. Shu KH, Wu MJ, Chen CH, Cheng CH, Lian JD. Outcome of kidney transplantation using organs from executed prisoners: is it justified beyond the ethical issue? J Chin Med Assoc. 2007; 70: 193-199.
21. Dew MA, Jacobs CL, Jowsey SG, Hanto R, Miller C, Delmonico FL. Guidelines for the psychosocial evaluation of living unrelated kidney donors in the United States. Am J Transplant. 2007; 5: 1047-1054.
22. Mazaris E, Papalois VE. Ethical issues in living donor kidney transplantation. Exp Clin Transplant. 2006; 4: 485-497.
23. Bruzzone P, Pretagostini R, Poli L, Rossi M, Berloco PB. Ethical considerations on kidney transplantation from living donors. Transplant Proc. 2005; 37: 2436-2438.
24. Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet. 2004; 364: 1611-1612.
25. KDIGO. Clinical Practice Guidelines for prevention, diagnosis, evaluation and treatment of hepatitis c in chronic kidney disease. KI. 2008; 73 (Suppl 109): S20-S45.
26. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. International summit of transplant tourism and organ trafficking convened by the transplantation Society and International Society of Nephrology in Istanbul, Turkey, April 30 - May 2, 2008.
27. Kliem V, Michel U, Burg M, Bock A, Chapman J, Dussol B, Fritsche L, Lebranchu Y, Oppenheimer F, Pohanka E, Savadori M, Tufveson G. Geographical prevalences, risk factors and impacts of hepatitis B and C after renal transplantation. Clin Nephrol. 2009; 71: 423-429.
28. Kamar N, Izopet J, Alric L, Guilbeaud-Frugier C, Rostaing L. Hepatitis C virus-related kidney disease: an overview. Clin Nephrol. 2008; 69: 149-160.